Navigation Links
Flow restrictors may reduce young children's accidental ingestion of liquid medications
Date:7/24/2013

Cincinnati, OH -- In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising. In a new study scheduled for publication in The Journal of Pediatrics, researchers studied whether adding flow restrictors to bottles can limit the amount of liquid medication a child could access even if child-resistant caps are missing or improperly closed.

Standard child-resistant packaging is designed to prevent or delay young children from opening bottles, giving caregivers reasonable time to intervene. However, in order for the packaging to work effectively, "Caregivers must correctly resecure the cap after each and every use. If the cap is not correctly resecured, children can open and drink whatever medication is in the bottle," according to Daniel S. Budnitz, MD, MPH, and colleagues from the Centers for Disease Control and Prevention, Emory University, and the Georgia Poison Center.

To address a potential second line of defense, the researchers studied whether flow restrictors (adapters added to the neck of a bottle to limit the release of liquid) had any effect on the ability of children to remove test liquid, as well as how much they were able to remove in a given amount of time. 110 children, aged 3-4 years, participated in two tests. In one test, the children were given an uncapped medication bottle with a flow restrictor, and in the other test, the children received either a traditional bottle without a cap or with an incompletely-closed child-resistant cap. For each test, children were given 10 minutes to remove as much test liquid as possible.

Within 2 minutes, 96% of bottles without caps and 82% of bottles with incompletely-closed ca
'/>"/>

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Soy-based S-equol supplement reduces metabolic syndrome risk factors
2. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
3. ONR taps research teams to help reduce jet noise
4. Nanocrystal-coated fibers might reduce wasted energy
5. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
6. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
7. Tax on salt could reduce cardiovascular disease deaths by 3 percent
8. How the ecological risks of extended bioenergy production can be reduced
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Researchers show prebiotic can reduce severity of colitis
11. CUNY Energy Institute battery system could reduce buildings electric bills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... examples of how wildlife loss leads to conflict among ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis ... for an interdisciplinary approach to tackle global biodiversity decline. ... 15% of the world,s people and provides protein for ... should come as no surprise that today,s unprecedented loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... identified several proteins in mice that might act as ... first step to finding a more reliable way to ... and teenagers use illegally to boost muscle and reduce ... in San Francisco today, scientists John Kopchick and Juan ...
... For those patients who receive the nearly 40 ... deficiency, a new oral option may soon exist. ... B12 deficiency can lead to a wide spectrum of ... Vitamin B12 deficiency is a significant health issue. Nearly ...
... ADHD-associated version of the human gene DRD4 is linked ... malnourishment in their settled cousins, according to new research ... University of Wisconsin-Milwaukee (UWM). A study by UWM ... Boston University and UNLV shows that a particular version ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Did the gene for ADHD help our nomadic ancestors? 2
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... (NYSE: SGP ) today announced that the ... review status to the company,s,New Drug Application (NDA) ... reverse the effects of certain,muscle relaxants, marketed in ... bromide. Muscle relaxants are used as part of,general ...
... The following statement was issued,today by the law firm of ... given that a class action lawsuit was filed in the,United ... on,behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: ... through June 13, 2007,inclusive (the "Class Period")., If you ...
... Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... 30, 2007. Pharmasset reported a net loss attributable ... share, as compared to a net loss,attributable to ...
Cached Biology Technology:Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... to test the crossreactivity of an antibody ... commonly used as blocking reagents or antigen ... different protein preparations on a nitrocellulose membrane. ... specificity, QC of purified antibodies, selection of ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
Biology Products: